Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.23 | 1.94 |
NAV | ₹285.10 | ₹428.09 |
Fund Started | 01 Aug 2005 | 04 Jun 1999 |
Fund Size | ₹1235.91 Cr | ₹3628.03 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 35.30% | 34.18% |
3 Year | 19.53% | 22.70% |
5 Year | 26.99% | 28.85% |
1 Year
3 Year
5 Year
Equity | 97.59% | 96.55% |
Cash | 2.30% | 3.37% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.07% |
Cipla Ltd. | 5.75% |
Dr. Reddy's Laboratories Ltd. | 5.28% |
Ajanta Pharma Ltd. | 4.58% |
Glenmark Pharmaceuticals Ltd. | 4.03% |
Gland Pharma Ltd. | 3.83% |
Apollo Hospitals Enterprise Ltd. | 3.54% |
Fortis Healthcare Ltd. | 3.25% |
Procter & Gamble Health Ltd. | 3.14% |
Divi's Laboratories Ltd. | 3.03% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.00% |
Max Healthcare Institute Ltd. | 6.22% |
Divi's Laboratories Ltd. | 6.05% |
Cipla Ltd. | 5.90% |
Lupin Ltd. | 5.19% |
Lonza Group Ag | 4.16% |
Mankind Pharma Ltd. | 4.15% |
Poly Medicure Ltd. | 3.60% |
Krishna Institute of Medical Sciences Ltd | 3.46% |
Jupiter Life Line Hospitals Ltd. | 3.45% |
Name | Kamal Gada | Tanmaya Desai |
Start Date | 02 May 2022 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 01 Aug 2005 | 04 Jun 1999 |
Description
Launch Date